Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Assets (2018 - 2025)

Arcturus Therapeutics Holdings' Assets history spans 8 years, with the latest figure at $271.1 million for Q4 2025.

  • For Q4 2025, Assets fell 21.19% year-over-year to $271.1 million; the TTM value through Dec 2025 reached $271.1 million, down 21.19%, while the annual FY2025 figure was $271.1 million, 21.19% down from the prior year.
  • Assets reached $271.1 million in Q4 2025 per ARCT's latest filing, down from $282.3 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $481.5 million in Q1 2021 to a low of $271.1 million in Q4 2025.
  • Average Assets over 5 years is $384.3 million, with a median of $390.7 million recorded in 2021.
  • Peak YoY movement for Assets: soared 567.74% in 2021, then crashed 32.43% in 2022.
  • A 5-year view of Assets shows it stood at $392.8 million in 2021, then increased by 14.66% to $450.4 million in 2022, then decreased by 4.66% to $429.4 million in 2023, then fell by 19.87% to $344.1 million in 2024, then decreased by 21.19% to $271.1 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Assets are $271.1 million (Q4 2025), $282.3 million (Q3 2025), and $309.3 million (Q2 2025).